LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
The purpose of the grant is to support the development of microneedle array patches (MAP) for self-administration of contraceptives for women in low- and middle-income countries (LMICs).
- The purpose of the grant is to support the development of microneedle array patches (MAP) for self-administration of contraceptives for women in low- and middle-income countries (LMICs).
- Bas van Buijtenen, CEO of LTS, comments: "At LTS, we care passionately about bringing patient friendly drug delivery to people worldwide.
- "The LTS MAP team is excited to have support from the Gates Foundation for the development of a long-acting contraceptive Microneedle Array Patch with LTS", said Dr. Frank Theobald, Head of MAP Program at LTS.
- LTS has also received funding from the Bill & Melinda Gates Foundation to support new formulation methods for mRNA, such as dissolvable microneedle array patches.